Abstract
No public abstract is available from the verified source records.
Alexandros Rampotas, Amy A. Kirkwood, Maximillian Hugo Brodermann, Nicola Maciocia, Fotios P. Panitsas, Sridhar Chaganti, Stella D. Bouziana, Emma Nicholson, Samantha Drummond, Michelle Lannon, Amy Publicover, Sharon Allen, Isaac Gannon, Andrew John King, Anne‐Louise Latif, Henry Crosland, Claire Roddie
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.1182/blood-2011-12-399287
10.1182/blood-2011-12-399287
10.1038/leu.2011.351
10.1038/leu.2011.351
Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the adult acute lymphoblastic leukemia working Group of the Japanese Society for transplantation and cellular therapy
10.1182/blood-2023-180602 · 2023
10.1111/bjh.15973
10.1111/bjh.15973
10.1056/nejmoa1609783
10.1056/nejmoa1609783
10.1182/bloodadvances.2021005978
10.1182/bloodadvances.2021005978
Real‐world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease‐positive B‐cell acute lymphoblastic leukemia: a CIBMTR database analysis
10.1182/blood-2025-6044 · 2025
10.1056/nejmoa2406526
10.1056/nejmoa2406526
10.1056/nejmoa1709866
10.1056/nejmoa1709866
10.1056/nejmoa2406526
10.1056/nejmoa2406526
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
openalex
Confidence 95%
datacite
Confidence 0%
10.1038/s41375-025-02532-7
10.1038/s41375-025-02532-7
10.1182/blood.2023022922
10.1182/blood.2023022922
10.1182/blood-2009-08-231217
10.1182/blood-2009-08-231217
10.1016/j.bbmt.2013.04.014
10.1016/j.bbmt.2013.04.014
10.1158/2643-3230.bcd-21-0095
10.1158/2643-3230.bcd-21-0095
10.1182/blood-2009-08-231217
10.1182/blood-2009-08-231217 · doi-reference
10.1182/blood.2023022922
10.1182/blood.2023022922 · doi-reference
10.1038/s41375-025-02532-7
10.1038/s41375-025-02532-7 · doi-reference
10.1056/nejmoa1709866
10.1056/nejmoa1709866 · doi-reference
10.1056/nejmoa2406526
10.1056/nejmoa2406526 · doi-reference
Real‐world outcomes with blinatumomab as a bridging therapy for allogeneic hematopoietic stem cell transplantation in relapsed/refractory or measurable residual disease‐positive B‐cell acute lymphoblastic leukemia: a CIBMTR database analysis
10.1182/blood-2025-6044 · doi-reference
10.1182/bloodadvances.2021005978
10.1182/bloodadvances.2021005978 · doi-reference
10.1056/nejmoa1609783
10.1056/nejmoa1609783 · doi-reference
10.1111/bjh.15973
10.1111/bjh.15973 · doi-reference
Outcomes and prognostic factors of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia: a study from the adult acute lymphoblastic leukemia working Group of the Japanese Society for transplantation and cellular therapy
10.1182/blood-2023-180602 · doi-reference
10.1038/leu.2011.351
10.1038/leu.2011.351 · doi-reference
10.1182/blood-2011-12-399287
10.1182/blood-2011-12-399287 · doi-reference
10.1158/2643-3230.bcd-21-0095
10.1158/2643-3230.bcd-21-0095 · doi-reference
10.1016/j.bbmt.2013.04.014
10.1016/j.bbmt.2013.04.014 · doi-reference